Influenza immunisation

The NIP and the WA Department of Health provide free influenza vaccines for people most at risk. This includes:

• Aboriginal people 6 months and over
• Children aged 6 months to under 5 years
• Primary school aged children (pre-primary to Year 6)
• People aged 6 months or over who have medical conditions such as:
  • heart disease
  • kidney disease
  • chronic respiratory conditions
  • chronic illnesses that required regular medical attention or hospitalisation in the previous year
  • chronic neurological conditions
  • immunocompromising conditions
  • haematological disorders
  • diabetes and other metabolic disorders
  • children aged 6 months to 10 years receiving long-term aspirin therapy.
• Vulnerable persons aged 6 months and older, including:
  • persons experiencing housing instability
  • residents in congregate living settings, such as residential aged care, disability care, mental health hostels and youth group houses.
• Pregnant people (at any stage of pregnancy)
• People 65 years and older
• WA Health staff members.

Please see the WA Immunisation Schedule and refer to the Influenza chapter on the Australian Immunisation Handbook (external site) for detailed advice, including vaccine dosage, and contraindications.

Providers should prioritise vaccinating in the months prior to the peak influenza season, which typically spans from July to October in WA. Influenza vaccination should continue to be offered while the influenza virus remains in circulation, and a valid vaccine is available.

For a brief summary of General Practice and hospital emergency department sentinel surveillance data on influenza-like illness, subscribe to Virus WAtch (a weekly electronic publication by CDCD and key collaborators).  For Australian Influenza Surveillance Reports, visit the Australian Government Department of Health and Aged Care website (external site).

Optimal protection against influenza occurs within 3 to 4 months following vaccination. During the influenza season, look for opportunities to provide influenza vaccination to persons at increased risk of influenza during their routine medical care visits.

If a person had a 2024 formulation influenza vaccine in late 2024 or early 2025, they are still recommended to receive a 2025 formulation influenza vaccine.

People planning to travel internationally should have the 2025 influenza vaccination at least 2 weeks prior to departure.

• Providers are highly recommended to review the 2025 Australian Technical Advisory Group on Immunisation (ATAGI) Statement on the administration of seasonal influenza vaccines (external site).
• Providers can also see the 2025 NIP influenza vaccination program advice for health professionals (external site).
• The influenza module on Immunisation education has been updated for 2025. The module and registration link can be found under the Immunisation education modules and registration accordion. Completion of the module is recommended for all immunisation providers and compulsory for those working under the CEO of Health SASA. The Immunisation education webpage also contains a link to the influenza update session.
• Influenza vaccine can be co-administered with most other vaccines (external site), including the COVID-19 vaccine.

It is a mandatory requirement for immunisation providers to report influenza vaccine administrations to the Australian Immunisation Register (external site). Providers need to ensure they are using the correct brand name, dose number and batch number.

The new vaccine type field should be used to records specific details of the vaccine administered. For example, NIP or state funded program. It is also important that you provide a response in the antenatal indicator field for females aged 10 to 65.

Refer to Immunisation provider information and resources webpage for more information.

AusVaxSafety (external site) conduct routine safety monitoring of seasonal influenza vaccines. Surveillance data are based on vaccine safety surveys sent in the days following influenza vaccination.

This rapid safety surveillance can provide reassurance to individuals that the influenza vaccines used in Australia are safe. To learn more about the latest vaccine safety data, including specific age and population groups, visit AusVaxSafety (external site).

Refer to the Adverse events following immunisation webpage for information about reporting any adverse events following an influenza vaccine.

The adjuvanted Fluad® Quad vaccine is preferentially recommended for persons aged 65 years or over. This product is not licensed or recommended for anyone aged <65 years.